MetaStat, Inc. to Present at the 2014 BIO CEO & Investor Conference in New York City on February 11, 2014admin
MONTCLAIR, NJ / February 5, 2014 / ACCESSWIRE / MetaStat, Inc. (OTCQB: MTST), a life science company focused on understanding and treating systemic metastasis, today announced that the company’s Chief Executive Officer, Oscar Bronsther, M.D., will present at the BIO CEO & Investor Conference on Tuesday, February 11, 2014 at 1:30 p.m. EST. The conference will be held at the Waldorf Astoria in New York. Dr. Bronsther will discuss MetaStat’s novel diagnostic and therapeutic approaches to systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body.
The company will be conducting investor meetings following its presentation in New York. Additional investor meetings will be held in San Francisco on Friday, February 7, 2014. Investors or potential partners attending the conference who wish to meet with Dr. Bronsther may contact the BIO Partnering Team at firstname.lastname@example.org.
To arrange a one-on-one meeting with management, please contact Robert Haag at email@example.com or 1-866-976-4784.
The BIO CEO & Investor Conference is one of the world’s largest investor conferences focused on established and emerging biotech companies. Each year, the conference handpicks presenters from companies that typically have a clinical-stage program as well as an upcoming clinical, regulatory or corporate catalyst. Attendees include institutional and venture investors whose primary activity is direct investment in research and development companies, as well as equity research analysts.
About MetaStat, Inc.
MetaStat is a life sciences company that develops and commercializes diagnostic products and novel therapeutics for the early and reliable prediction and treatment of systemic metastasis, the process by which cancer spreads from a primary tumor through the bloodstream to other areas of the body. MetaStat is focused on breast, prostate, lung and colorectal cancers, where systemic metastasis is responsible for approximately 90% of all deaths. The company’s function-based diagnostic platform technology is based on the identification and understanding of the pivotal role of the mena protein and its isoforms, a common pathway for the development of systemic metastatic disease in all epithelial-based solid tumors. Both the MetaSite Breast™ and MenaCalc™ product lines are designed to accurately stratify patients based on their individual risk of metastasis and to allow clinicians to better “customize” cancer treatment decisions by positively identifying patients with a high-risk of metastasis who need aggressive therapy and by sparing patients with a low-risk of metastasis from the harmful side effects and expense of chemotherapy. Additionally, the MenaBloc™ therapeutic program aims to build upon mena biology and alternative splicing events as a driver of disease progression to exploit novel targets that provide precision medicines in oncology.
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the company undertakes no obligation to update such statements.
Media Contact Information
ProActive Capital Group, LLC
Source: MetaStat, Inc.
Posted: February 5th, 2014 under ACCESSWIRE.